Kidney Cancer Trial, Recruiting (NCT05287464)

Kidney Cancer Trial, Recruiting NCT05287464 Sponsor: Hospital of Macerata Condition: Kidney Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05287464 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Kidney Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be older than 18 years of age
You have been diagnosed with a type of kidney cancer called renal cell carcinoma (RCC) — either "clear cell" or "non-clear cell" type — confirmed by a tissue or cell sample test
Your cancer has been confirmed to have spread to other parts of the body (metastatic disease), either through a tissue sample or a scan
Your first treatment for this cancer was one of these specific drug combinations: nivolumab + ipilimumab, nivolumab + cabozantinib, pembrolizumab + axitinib, pembrolizumab + lenvatinib, avelumab + axitinib, or atezolizumab + bevacizumab

Who may not be able to join:

You have not had your kidney cancer diagnosis confirmed through a tissue sample test
It has not been confirmed through a tissue sample or scan that your cancer has spread to other parts of the body
Your first treatment was an immunotherapy drug combination that is not one of the six specific combinations listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +3907332572960

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05287464

Sponsor: Hospital of Macerata

Phase: Not Applicable

Status: Recruiting

Condition: Kidney Cancer

Trial contact: +3907332572960

More information: https://clinicaltrials.gov/study/NCT05287464

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be older than 18 years of age
You have been diagnosed with a type of kidney cancer called renal cell carcinoma (RCC) — either "clear cell" or "non-clear cell" type — confirmed by a tissue or cell sample test
Your cancer has been confirmed to have spread to other parts of the body (metastatic disease), either through a tissue sample or a scan
Your first treatment for this cancer was one of these specific drug combinations: nivolumab + ipilimumab, nivolumab + cabozantinib, pembrolizumab + axitinib, pembrolizumab + lenvatinib, avelumab + axitinib, or atezolizumab + bevacizumab

Who may not be able to join:

You have not had your kidney cancer diagnosis confirmed through a tissue sample test
It has not been confirmed through a tissue sample or scan that your cancer has spread to other parts of the body
Your first treatment was an immunotherapy drug combination that is not one of the six specific combinations listed above

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hospital of Macerata

Registry

ClinicalTrials.gov

Start date

10 March 2022

Est. completion

1 June 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Progression-Free Survival (PFS); Overall Survival (OS); Overall Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov